Eshghi Gholamreza, Khezrian Leila, Esna Ashari Fariba
Department of Dermatology, Psoriasis Research Center, Farshchian Hospital, Hamadan University of Medical Sciences, Hamadan, Iran.
Acta Med Iran. 2016 Jan;54(1):67-71.
Melasma is a common acquired skin disorder. While different treatments are currently being used, in many cases it is refractory to treatment. According to the effects of topical steroids in decreasing skin pigmentation, we studied the efficacy of this new method for treatment of melasma. A total of 42 women with facial melasma, admitted to the department of dermatology of Hamadan, were enrolled in the study. They were divided randomly into two groups (A and B), group A (case) received subepidermal triamcinolone injections with a dose of 4 mg per cc and 5 mm intervals until complete blanching of melasma lesions, and group B (control) received Kligman's formula (hydroquinone 5%, tretinoin 0.1%, and dexamethasone 0.1%). At the first visit, we completed the MASI score papers, and we repeated that at weeks 4 and 8 of the study. We followed them for two months, every two weeks. At each visit, side effects and clinical response to treatment were noted. A decrease in MASI was observed in both group (11.57 ± 4.33 vs 9.31 ± 3.75 at 4th week and vs 8.01 ± 3.1 at 8th week, P-value < 0.001 in group A, and 10.46 ± 5.61 vs 9.76 ± 5.21 at 4th week and vs 8.96 ± 4.96 at 8th week, P-value< 0.001 in group B). In comparison between 2 groups, response to treatment was much better in group A than group B (P-value<0.001). In comparison to topical treatments, based on these findings, triamcinolone microinjection is a new, safe and strong therapeutic method for treatment of melasma.
黄褐斑是一种常见的获得性皮肤病。虽然目前正在使用不同的治疗方法，但在许多情况下，它对治疗具有难治性。根据外用类固醇在减少皮肤色素沉着方面的作用，我们研究了这种新方法治疗黄褐斑的疗效。共有42名面部黄褐斑女性患者入住哈马丹皮肤科，纳入本研究。她们被随机分为两组（A组和B组），A组（病例组）接受皮下注射曲安奈德，剂量为每立方厘米4毫克，间隔5毫米，直至黄褐斑皮损完全变白，B组（对照组）接受克利格曼配方（5%氢醌、0.1%维甲酸和0.1%地塞米松）。在首次就诊时，我们完成了MASI评分表，并在研究的第4周和第8周重复进行。我们对她们进行了两个月的随访，每两周一次。每次就诊时，记录副作用和治疗的临床反应。两组的MASI均有所下降（A组第4周为11.57±4.33，第8周为8.01±3.1，P值<0.00!；B组第4周为10.46±5.61，第8周为8.96±4.96，P值<0.001）。两组比较，A组的治疗反应明显优于B组（P值<0.001）。基于这些发现，与局部治疗相比，曲安奈德微量注射是一种治疗黄褐斑的新的、安全且有效的治疗方法。
